| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| TRAIL R2 | HOT TR2-H5229 | Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag, low endotoxin | Human | HEK293 | ![]() | SDS-PAGE | $285.00 100ug | |
| TRAIL R2 | HOT TR2-H5255 | Human TRAIL R2 / DR5 / TNFRSF10B Protein, Fc Tag, low endotoxin | Human | HEK293 | ![]() | SDS-PAGE | $285.00 100ug | |
| TRAIL R2 | HOTAvitag TR2-H82E6 | Biotinylated Human TRAIL R2 / DR5 / TNFRSF10B Protein, Avitag™,His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | |
| TRAIL R2 | Cynomolgus TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag, low endotoxin (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $285.00 100ug | ||
| TRAIL R2 | FITC-Labeled Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $330.00 25ug | ||
| TRAIL R2 | Mouse TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag | Mouse | HEK293 | ![]() | SDS-PAGE | $285.00 100ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Dulanermin (Shanghai GeBaiDe) | Phase 3 Clinical | Shanghai Gebaide Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | 詳細 | |
| Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) | Phase 3 Clinical | Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd | Neoplasms | 詳細 | |
| TLY-012 | TLY-012 | Phase 1 Clinical | Theraly Fibrosis | Fibrosis; Liver Cirrhosis; Pancreatitis; Pancreatitis, Chronic; Scleroderma, Systemic | 詳細 |
| BI-905711 | BI-905711 | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Cholangiocarcinoma; Gastrointestinal Neoplasms; Pancreatic Neoplasms | 詳細 |
| Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) | CTB-006 | Phase 1 Clinical | Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd | Solid tumours | 詳細 |
| Ozekibart | JCT-205; INBRX-109 | Phase 1 Clinical | Inhibrx Inc | Adenocarcinoma | 詳細 |
| TRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Neoplasms | 詳細 | |
| RC-248 | RC-248; RC248 | Phase 1 Clinical | Solid tumours | 詳細 | |
| IBI-3004 | IBI-3004; IBI3004 | Phase 1 Clinical | Colorectal Neoplasms; Solid tumours | 詳細 | |
| Oba-01 | Oba-01; Oba01 | Phase 1 Clinical | Yantai Heyuanaidisi Biomedical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Aponermin | Approved | Beijing Shadong Biotech Co Ltd | 沙艾特, Shaite | Mainland China | Multiple Myeloma | Wuhan Hiteck Biological Pharma Co Ltd | 2023-11-02 | Multiple Myeloma | 詳細 |